- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Indrayani Biotech Limited has announced a board meeting on 12th June to approve the financial results for the quarter and half-year. The audited consolidated financials for the year ended March 31, 2025, show revenue from operations at Rs 130.23 Cr, down from Rs 166.23 Cr last year. The company reported a consolidated loss of Rs 6.11 Cr compared to a profit of Rs 10.42 Cr in the previous year. EBITDA turned negative for the year, impacted by higher expenses and finance costs. The balance sheet reflects total assets of Rs 268.17 Cr and equity of Rs 99.92 Cr. Operating cash flows remained negative at Rs 6.74 Cr. The audit concluded with an unmodified opinion.